Folotyn for Non-Hodgkin's Lymphoma Roosevelt NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Steven Edward Vogl
(718) 519-7774
2220 Tiemann Ave
Bronx, NY
MAGANLAL MISTRY, MD
(718) 615-3777
3245 Nostrand Avenue
Brooklyn, NY
RANJEET GROVER, MD
(718) 747-1327
12111 Keel Court
College Point, NY
Mark M Moradi, MD
718-380-8080
Roslyn Heights, NY
John David Hardin, MD
870-541-7495
111 E 210th St
Bronx, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
LEO WIENER, MD
(516) 742-5353
520 Franklin Avenue
Garden City, NY
ROBERT GALLAGHER, MD
(718) 920-4057
111 East 210Th Street
Bronx, NY
Doron Weiner, MD
516-546-5000
2209 Merrick Rd
Merrick, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Roosevelt NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Roosevelt NY